Results 11 to 20 of about 20,527 (318)

Conjunctivitis in dupilumab clinical trials [PDF]

British Journal of Dermatology, 2019
Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients
Bolanle Akinlade, Emma Guttman‐Yassky, Marjolein de Bruin‐Weller, Eric L. Simpson, Andrew Blauvelt, Michael J. Cork, Errol P. Prens, Penny A. Asbell, Esen K. Akpek, Jonathan Corren, Claus Bachert, Ikuo Hirano, Jonathan Weyne, Andrew Korotzer, Z. Chen, Thomas Hultsch, Xindong Zhu, Jeff Davis, Leda Mannent, Jennifer D. Hamilton, Alejandro Teper, Heribert Staudinger, E. Rizova, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel, Marius Ardeleanu, Andreas Wollenberg   +27 more
openalex   +9 more sources

Mechanisms of Dupilumab [PDF]

Clinical & Experimental Allergy, 2019
AbstractThe Th2 cytokines interleukin 4 (IL‐4) and IL‐13 and the heterodimeric IL‐4 receptor (IL‐4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL‐4 receptor alpha chain (IL‐4Rα), common to both IL‐4R complexes: type 1 (IL‐4Rα/γc; IL‐4 ...
Hani Harb, Talal A. Chatila
openaire   +3 more sources

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

The Role of Dupilumab in Severe Asthma [PDF]

Biomedicines, 2021
Dupilumab is a fully humanized monoclonal antibody, capable of inhibiting intracellular signaling of both interleukin (IL)-4 and IL-13. These are two molecules that, together with other proinflammatory cytokines such as IL-5 and eotaxins, play a pivotal role in orchestrating the airway inflammatory response defined as Type 2 (T2) inflammation, driven ...
Ricciardolo F. L. M., Bertolini F., Carriero V.   +2 more
openaire   +4 more sources

Dupilumab-Induced Pancreatitis

ACG Case Reports Journal, 2023
ABSTRACT Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies.
Jasti, Vivek V., McCarthy, Sean T., Govani, Shail M.   +2 more
openaire   +2 more sources

Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]

, 2020
Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C, Lopes, A, Lopes, C, Sokolova, A   +3 more
core   +1 more source

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos, Baldrich, Esther Serra, Herráez, L., Jáuregui, Ignacio, Martín-Santiago, Ana, Ortiz de Frutos, Javier, Sastre, Joaquin, Silvestre, Juan Francisco, Universitat Autònoma de Barcelona, Valero, Antonio   +9 more
core   +3 more sources

Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]

, 2019
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus, Ren, Lei, Zhang, Luo, Zhang, Nan   +3 more
core   +1 more source

Dupilumab-associated blepharoconjunctivitis

American Journal of Ophthalmology Case Reports, 2019
To report a case of dupilumab-associated blepharoconjunctivitis.A 48 year-old Caucasian male presented with bilateral blepharitis, multiple chalazia, dry eye disease and significant papillary conjunctivitis. The past medical history included fourteen years of severe atopic dermatitis.
Suzanne W. Sherman, Leejee H. Suh, Sefy A. Paulose, Lora R. Dagi Glass   +3 more
openaire   +3 more sources

Dupilumab in pediatric dermatology

Journal of Dermatological Treatment, 2020
Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit of the IL-4 and IL-13 receptor. This novel agent has received a license for the treatment of moderate-to-severe atopic dermatitis in patients aged ≥12 years. However, data on the dupilumab use in the pediatric population are still extremely limited.
Kerasia-Maria Plachouri, Sophia Georgiou
openaire   +2 more sources